Research

UK Researchers Link a New Non-Mutated Protein to Dementia

Peter Nelson, M.D., Ph.D., of the Sanders-Brown Center on Aging. Pete Comparoni | UK Photo
Peter Nelson, M.D., Ph.D., of the Sanders-Brown Center on Aging. Pete Comparoni | UK Photo

LEXINGTON, Ky. (Feb. 2, 2022) – A team of researchers from the University of Kentucky’s Sanders-Brown Center on Aging (SBCoA) is working to identify new proteins that are destructive to the brain. They know that about 25% of individuals, and 50% of individuals with Alzheimer disease, have the genetic mutation APOE ε4 allele — a known risk factor for the disease.

Through a recent study, researchers were surprised to find that even in the brains of patients without the disease-driving mutation, ApoE proteins were enhanced in dementia. Their findings appear in The American Journal of Pathology, published by Elsevier.

“Dementia is very complex, but you can simplify it: the disease is caused by ‘gloppy proteins’ in the brain,” said lead investigator Peter T. Nelson, M.D., Ph.D., director of neuropathology at SBCoA and a professor in UK’s Department of Pathology. “I’m not making light of it; these ‘sticky’ misfolded proteins often end up destroying the brain, the mind, the memories and everything else for millions of people who suffer from dementia. We want to understand specifically which proteins are the problem.”

The investigators looked at 40 participants from the University of Kentucky Alzheimer’s Disease Center autopsy cohort — Kentucky residents who have agreed to donate their brains at time of death. The subjects ranged from cognitively normal to severe dementia. Although previous studies have examined the human amygdala proteome, none have reported on a sample of this size with dementia subjects and control subjects for comparison.

As anticipated, portions of proteins previously associated with neurodegenerative diseases were found in the brains of patients with dementia, including proteins called Tau (associated with neurofibrillary tangles), Aβ (associated with amyloid plaques), and α-Synuclein (associated with Lewy Body disease). Aβ and α-Synuclein correlated strongly with clinical diagnosis of dementia. Tau and Aβ proteins, but not α-Synuclein, were occasionally detectible in cognitively normal subjects and those with mild cognitive impairment. Overall, Nelson says the findings were in line with their expectations.

“Like many big stories in science, it is not entirely novel. Other researchers have produced similar results," said Nelson. "However, this finding strongly underscores the potential for ApoE to promote dementia, even in persons that don’t carry the ‘bad’ gene.”

The data revealed a close correlation between dementia diagnosis and the detection of ApoE peptides in the brain. The correlation with dementia for ApoE was even stronger than that seen for Tau, Aβ, or α-Synuclein. Researchers found that the ApoE peptides were significantly enriched even in dementia patients who lack the APOE ε4 allele. The results emphasize the ApoE protein may play an active disease-driving role in its own right, rather than just being an “upstream” genetic risk factor.

“Our study adds to an evolving appreciation of multiple misfolded proteins in the human brain and moves the field forward by emphasizing that ApoE may be a stong contributor to the dementia prototype, even in individuals who do not have the disease-driving version of the APOE gene,” said Nelson. “Even in persons lacking the APOE ε4 allele, ApoE may indeed be among the most impactful ‘gloppy proteins’ in aging brains.”

Research reported in this publication was supported by the National Institute on Aging of the National Institutes of Health under Award Numbers P30AG072946, R01AG042419, R01AG042475, R01AG061111, R01 AG057187 R21AG061551, R01AG060056, R01AG062550; the National Institute of Neurological Disorders and Stroke of the National Institutes of Health under Award Numbers RF1NS118584 and R21NS095299; and the National Center for Research Resources of the National Institutes of Health under Award Number S10 RR029127. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

This material is based upon work supported by the Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development, Biomedical Laboratory Research and Development. The views expressed in this article are those of the authors and do not necessarily reflect the position or policy of the Department of Veterans Affairs or the United States government.

 

The University of Kentucky is increasingly the first choice for students, faculty and staff to pursue their passions and their professional goals. In the last two years, Forbes has named UK among the best employers for diversity, and INSIGHT into Diversity recognized us as a Diversity Champion four years running. UK is ranked among the top 30 campuses in the nation for LGBTQ* inclusion and safety. UK has been judged a “Great College to Work for" three years in a row, and UK is among only 22 universities in the country on Forbes' list of "America's Best Employers."  We are ranked among the top 10 percent of public institutions for research expenditures — a tangible symbol of our breadth and depth as a university focused on discovery that changes lives and communities. And our patients know and appreciate the fact that UK HealthCare has been named the state’s top hospital for five straight years. Accolades and honors are great. But they are more important for what they represent: the idea that creating a community of belonging and commitment to excellence is how we honor our mission to be not simply the University of Kentucky, but the University for Kentucky.